Sulzer (SUN) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
16 Dec, 2025Executive summary
Achieved strong 2024 results with double-digit growth in sales and order intake, reflecting successful strategy execution and focus on essential, structurally growing industries such as energy, water, chemicals, and green minerals.
Significant improvements in profitability and financial strength, supported by Sulzer Excellence initiatives and operational execution.
Continued investments in operational excellence, innovation, and customer-centricity, including new test and innovation centers in Singapore, Mexico, and Europe.
Financial highlights
2024 sales reached CHF 3,530.6m, up 10.8% year-over-year in constant currencies; order intake rose 10.8% to CHF 3,848.6m.
EBITDA increased to CHF 436.2m, with operational profit up nearly 25% compared to 2023; EBITA up 24.7% to CHF 436.2m; EBIT up 21.8% to CHF 383m; Net Income grew 20% to CHF 265m.
Free cash flow was CHF 234.9m, impacted by timing of a large customer payment, higher CapEx, working capital, and tax payments.
Return on capital employed rose by 200 basis points to 19.7%.
Dividend proposed to increase from CHF 3.75 to CHF 4.25 per share, with a payout ratio of 46.7% of core net income.
Outlook and guidance
2025 guidance: order intake up 2–5%, sales up 5–8%, EBITDA margin above 15%, with less cost for Sulzer Excellence implementation than in 2024.
Execution on high backlog is a key focus; revenue growth expected to be more dynamic in H1 2025.
Long-term strategy targets above-average organic growth in structurally growing markets.
Latest events from Sulzer
- Record sales, profit, and margins support a higher dividend and positive 2026 outlook.SUN
Q4 202526 Feb 2026 - Order and sales growth drove higher profitability and upgraded 2024 guidance.SUN
H1 20242 Feb 2026 - Targets above-market growth, >17% EBITDA margin, and >22% ROCE by 2028, fully self-financed.SUN
CMD 20241 Feb 2026 - Order intake recovers, Services grow double digits, Chemtech hit by delays; guidance reaffirmed.SUN
Q3 2025 TU2 Nov 2025 - Sales, EBITDA, and net income up; Chemtech lagged, outlook and dividend increased.SUN
H1 202524 Jul 2025 - Stable Q1 order intake and confirmed guidance, with strong Flow and Services growth.SUN
Q1 2025 TU23 Jun 2025 - Order intake up 9.2% year-over-year; full-year guidance and profitability targets reaffirmed.SUN
Q3 2024 TU13 Jun 2025